SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

Download PDF Copy

By Sally Robertson, B.Sc.Jul 31 2019Reviewed by Kate Anderton, B.Sc. (Editor)

Researchers have published reassuring findings that sodium-glucose cotransporter-2 (SGLT-2) inhibitors for the treatment of type 2 diabetes do not seem to increase the risk of urinary tract infections (UTIs) over other anti-diabetic medications.

“In a large cohort of patients seen in routine clinical practice, [the] risk for severe and non-severe UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications,” write Chintan Dave from Rutgers University and colleagues from Brigham and Women’s Hospital and Harvard Medical School.